When Will CardieX Limited (ASX:CDX) Turn A Profit?

CardieX Limited (ASX:CDX) is possibly approaching a major achievement in its business, so we would like to shine some light on the company. CardieX Limited engages in the design, manufacture, and marketing of medical devices used in cardiovascular health management in the Americas, Europe, and the Asia Pacific. On 30 June 2024, the AU$61m market-cap company posted a loss of AU$6.8m for its most recent financial year. The most pressing concern for investors is CardieX's path to profitability – when will it breakeven? Below we will provide a high-level summary of the industry analysts’ expectations for the company.

Check out our latest analysis for CardieX

CardieX is bordering on breakeven, according to some Australian Medical Equipment analysts. They expect the company to post a final loss in 2025, before turning a profit of AU$24m in 2026. The company is therefore projected to breakeven just over a year from now. How fast will the company have to grow each year in order to reach the breakeven point by 2026? Working backwards from analyst estimates, it turns out that they expect the company to grow 91% year-on-year, on average, which is rather optimistic! If this rate turns out to be too aggressive, the company may become profitable much later than analysts predict.

Underlying developments driving CardieX's growth isn’t the focus of this broad overview, however, bear in mind that generally a high forecast growth rate is not unusual for a company that is currently undergoing an investment period.

One thing we would like to bring into light with CardieX is its relatively high level of debt. Typically, debt shouldn’t exceed 40% of your equity, which in CardieX's case is 79%. A higher level of debt requires more stringent capital management which increases the risk around investing in the loss-making company.

Next Steps:

There are too many aspects of CardieX to cover in one brief article, but the key fundamentals for the company can all be found in one place – CardieX's company page on Simply Wall St. We've also compiled a list of key factors you should further research:

1. Valuation: What is CardieX worth today? Has the future growth potential already been factored into the price? The intrinsic value infographic in our free research report helps visualize whether CardieX is currently mispriced by the market.
2. Management Team: An experienced management team on the helm increases our confidence in the business – take a look at who sits on CardieX’s board and the CEO’s background.
3. Other High-Performing Stocks: Are there other stocks that provide better prospects with proven track records? Explore our free list of these great stocks here.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.